公开(公告)号：FI970768A0

公开(公告)日：1997-02-24

申请号：FI970768

申请日：1997-02-24

Applicant: HOECHST AG

Inventor： SEDLACEK HANS-HARALD ,  BOSSLET KLAUS ,  MUELLER ROLF

IPC: C12N15/09 ,  A61K9/127 ,  A61K35/76 ,  A61K38/00 ,  A61K38/21 ,  A61K38/22 ,  A61K38/44 ,  A61K38/46 ,  A61K38/55 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61P7/02 ,  A61P9/08 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/47 ,  C07K14/475 ,  C12N15/00 ,  C12N15/85 ,  C12P21/02 ,  C12R1/91 ,  C12R1/92 ,  C12N

Abstract: PCT No. PCT/EP95/03370 Sec. 371 Date Apr. 18, 1997 Sec. 102(e) Date Apr. 18, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06940 PCT Pub. Date Mar. 7, 1996A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.

公开(公告)号：FI970768A

公开(公告)日：1997-02-24

申请号：FI970768

申请日：1997-02-24

Applicant: HOECHST AG

Inventor： SEDLACEK HANS-HARALD ,  BOSSLET KLAUS ,  MUELLER ROLF

IPC: C12N15/09 ,  A61K9/127 ,  A61K35/76 ,  A61K38/00 ,  A61K38/21 ,  A61K38/22 ,  A61K38/44 ,  A61K38/46 ,  A61K38/55 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61P7/02 ,  A61P9/08 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/47 ,  C07K14/475 ,  C12N15/00 ,  C12N15/85 ,  C12P21/02 ,  C12R1/91 ,  C12R1/92 ,  C12N

Abstract: PCT No. PCT/EP95/03370 Sec. 371 Date Apr. 18, 1997 Sec. 102(e) Date Apr. 18, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06940 PCT Pub. Date Mar. 7, 1996A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.